Literature DB >> 9414242

Localization and molecular interactions of mitoxantrone within living K562 cells as probed by confocal spectral imaging analysis.

A Feofanov1, S Sharonov, I Kudelina, F Fleury, I Nabiev.   

Abstract

Studying mechanisms of drug antitumor action is complicated by the lack of noninvasive methods enabling direct monitoring of the state and interactions of the drugs within intact viable cells. Here we present a confocal spectral imaging (CSI) technique as a method of overcoming this problem. We applied this method to the examination of localization and interactions of mitoxantrone (1, 4-dihydroxy-5, 8-bis-[([2-(2-hydroxyethyl)-amino]ethyl)amino]-9,10-anthracenedione dihydrochloride), a potent antitumor drug, in living K562 cells. A two-dimensional set of fluorescence spectra of mitoxantrone (MITOX) recorded with micron resolution within a drug-treated cell was analyzed to reveal formation of drug-target complexes and to create the maps of their intracellular distribution. The analysis was based on detailed in vitro modeling of drug-target (DNA, RNA, DNA topoisomerase II) interactions and environmental effects affecting drug fluorescence. MITOX exposed to aqueous intracellular environment, MITOX bound to hydrophobic cellular structures, complexes of MITOX with nucleic acids, as well as the naphtoquinoxaline metabolite of MITOX were simultaneously detected and mapped in K562 cells. These states and complexes are known to be immediately related to the antitumor action of the drug. The results obtained present a basis for the subsequent quantitative analysis of concentration and time-dependent accumulation of free and bound MITOX within different compartments of living cancer cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9414242      PMCID: PMC1181233          DOI: 10.1016/S0006-3495(97)78356-5

Source DB:  PubMed          Journal:  Biophys J        ISSN: 0006-3495            Impact factor:   4.033


  21 in total

1.  Persistent intracellular binding of mitoxantrone in a human colon carcinoma cell line.

Authors:  R A Roberts; A E Cress; W S Dalton
Journal:  Biochem Pharmacol       Date:  1989-12-01       Impact factor: 5.858

2.  Multicolour spectral karyotyping of mouse chromosomes.

Authors:  M Liyanage; A Coleman; S du Manoir; T Veldman; S McCormack; R B Dickson; C Barlow; A Wynshaw-Boris; S Janz; J Wienberg; M A Ferguson-Smith; E Schröck; T Ried
Journal:  Nat Genet       Date:  1996-11       Impact factor: 38.330

Review 3.  Molecular and biochemical pharmacology of mitoxantrone.

Authors:  F E Durr; R E Wallace; R V Citarella
Journal:  Cancer Treat Rev       Date:  1983-12       Impact factor: 12.111

4.  Horseradish peroxidase-catalyzed oxidation of mitoxantrone: spectrophotometric and electron paramagnetic resonance studies.

Authors:  K Reszka; P Kolodziejczyk; J W Lown
Journal:  J Free Radic Biol Med       Date:  1986

5.  Interaction of the peroxidase-derived metabolite of mitoxantrone with nucleic acids. Evidence for covalent binding of 14C-labeled drug.

Authors:  K Reszka; J A Hartley; P Kolodziejczyk; J W Lown
Journal:  Biochem Pharmacol       Date:  1989-12-01       Impact factor: 5.858

6.  Quantitative study of doxorubicin in living cell nuclei by microspectrofluorometry.

Authors:  M Gigli; S M Doglia; J M Millot; L Valentini; M Manfait
Journal:  Biochim Biophys Acta       Date:  1988-05-06

7.  Experimental antitumor activity of aminoanthraquinones.

Authors:  R K Johnson; R K Zee-Cheng; W W Lee; E M Acton; D W Henry; C C Cheng
Journal:  Cancer Treat Rep       Date:  1979-03

8.  Relationship between the pharmacological activity of antitumor drugs Ametantrone and mitoxantrone (Novatrone) and their ability to condense nucleic acids.

Authors:  J Kapuscinski; Z Darzynkiewicz
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

9.  Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics.

Authors:  S Fujimoto; M Ogawa
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

10.  Interactions of antitumor agents Ametantrone and Mitoxantrone (Novatrone) with double-stranded DNA.

Authors:  J Kapuscinski; Z Darzynkiewicz
Journal:  Biochem Pharmacol       Date:  1985-12-15       Impact factor: 5.858

View more
  10 in total

1.  Cancer cell injury by cytotoxins from cobra venom is mediated through lysosomal damage.

Authors:  Alexei V Feofanov; George V Sharonov; Maria V Astapova; Dmitriy I Rodionov; Yuriy N Utkin; Alexander S Arseniev
Journal:  Biochem J       Date:  2005-08-15       Impact factor: 3.857

2.  Formaldehyde activation of mitoxantrone yields CpG and CpA specific DNA adducts.

Authors:  B S Parker; S M Cutts; C Cullinane; D R Phillips
Journal:  Nucleic Acids Res       Date:  2000-02-15       Impact factor: 16.971

3.  Confocal raman microspectroscopy and imaging study of theraphthal in living cancer cells.

Authors:  A V Feofanov; A I Grichine; L A Shitova; T A Karmakova; R I Yakubovskaya; M Egret-Charlier; P Vigny
Journal:  Biophys J       Date:  2000-01       Impact factor: 4.033

4.  Short-chain glycoceramides promote intracellular mitoxantrone delivery from novel nanoliposomes into breast cancer cells.

Authors:  Lília R Cordeiro Pedrosa; Timo L M Ten Hagen; Regine Süss; Albert van Hell; Alexander M M Eggermont; Marcel Verheij; Gerben A Koning
Journal:  Pharm Res       Date:  2014-10-16       Impact factor: 4.200

5.  Mitoxantrone suppresses vascular smooth muscle cell (VSMC) proliferation and balloon injury-induced neointima formation: An in vitro and in vivo study.

Authors:  Yuan Teng; Ziyi Wang; Wen Li; Jianxing Yu; Zhen Shan; Chun Liang; Shenming Wang
Journal:  Bosn J Basic Med Sci       Date:  2017-11-20       Impact factor: 3.363

6.  Quantitative confocal spectral imaging analysis of mitoxantrone within living K562 cells: intracellular accumulation and distribution of monomers, aggregates, naphtoquinoxaline metabolite, and drug-target complexes.

Authors:  A Feofanov; S Sharonov; F Fleury; I Kudelina; I Nabiev
Journal:  Biophys J       Date:  1997-12       Impact factor: 4.033

7.  Autophagy (but not metabolism) is a key event in mitoxantrone-induced cytotoxicity in differentiated AC16 cardiac cells.

Authors:  Ana Reis-Mendes; Félix Carvalho; Fernando Remião; Emília Sousa; Maria de Lourdes Bastos; Vera Marisa Costa
Journal:  Arch Toxicol       Date:  2022-10-10       Impact factor: 6.168

8.  Proapoptotic activity of cytochrome c in living cells: effect of K72 substitutions and species differences.

Authors:  Rita V Chertkova; George V Sharonov; Alexei V Feofanov; Ol'ga V Bocharova; Ramil F Latypov; Boris V Chernyak; Alexander S Arseniev; Dmitry A Dolgikh; Mikhail P Kirpichnikov
Journal:  Mol Cell Biochem       Date:  2008-04-19       Impact factor: 3.396

9.  Approved Anti-cancer Drugs Target Oncogenic Non-coding RNAs.

Authors:  Sai Pradeep Velagapudi; Matthew G Costales; Balayeshwanth R Vummidi; Yoshio Nakai; Alicia J Angelbello; Tuan Tran; Hafeez S Haniff; Yasumasa Matsumoto; Zi Fu Wang; Arnab K Chatterjee; Jessica L Childs-Disney; Matthew D Disney
Journal:  Cell Chem Biol       Date:  2018-06-28       Impact factor: 8.116

10.  Studies on the binding affinity of anticancer drug mitoxantrone to chromatin, DNA and histone proteins.

Authors:  Zahra Hajihassan; Azra Rabbani-Chadegani
Journal:  J Biomed Sci       Date:  2009-03-11       Impact factor: 8.410

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.